Tumour growth and nitrogen metabolism in the host (Review)

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 479-486

  Argilés, Josep M ^a   Costelli, Paola ^b   Carbó, Neus ^a   Pallarés Trujillo, Javier ^a   López Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Amino acids; Cancer cachexia; Cytokines; Muscle wasting; Tumour metabolism

Indexed keywords

CYTOKINE; NITROGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CACHEXIA; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; CACHEXIA; CYTOKINES; HUMANS; NEOPLASMS; NITROGEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033088951     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.3.479     Document Type: Review

References (142)

1. Mider GB: Some aspects of nitrogen and energy metabolism in cancerous subjects. Cancer Res 11: 821-829, 1951.
2. Shapot VS: On the multiform relationships between the tumor and the host. Adv Cancer Res 30: 89-150, 1979.
3. Lundholm K, Bylund A, Holm J and Scherstén T: Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 12: 465-473, 1976.
4. Argilés JM and Azcón-Bieto J: The metabolic environment of cancer. Mol Cell Biochem 81: 3-17, 1988.
5. Snell K: Enzymes of serine metabolism in normal and neoplastic rat tissues. Biochim Biophys Acta 843: 276-281, 1985.
6. Snell K and Weber G: Enzymic imbalance in serine metabolism in rat hepatomas. Biochem J 233: 617-620, 1986.
7. Goodlad GAJ and Clark CM: Activity of gastrocnemius and soleus polyribosomes in rats bearing the Walker 256 carcinoma. Eur J Cancer 8: 631-647, 1972.
8. Blackburn GL, Maini BS, Bistrian BR and McDermott WV Jr: The effect of cancer on nitrogen, electrolyte and mineral metabolism. Cancer Res 37: 2348-2352, 1977.
9. Odell WD and Wolfsen AR: Hormones from tumours: are they ubiquitous? Am J Med 68: 317-318, 1980.
10. Gosporadowicz D and Moran S: Growth factors in mammalian cell cultures. Ann Biochem 45: 531-557, 1976.
11. Todaro GI and De Larco JE: Growth factors produced by sarcoma virus transformed cells. Cancer Res 38: 4147-4154, 1978.
12. Goustin AS, Leof EB, Shipley GD and Moses AL: Growth factors and cancer. Cancer Res 46: 1015-1029, 1986.
13. Levin L and Gevers W: Metabolic alterations in cancer II. S Afr Med J 59: 518-521, 1981.
14. Medina MA, Sánchez-Jiménez F, Marquez J, Rodriguez-Quesada A and Nuñez de Castro I: Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem 113: 1-15, 1992.
15. Wagle SR, Morris HP and Weber G: Comparative biochemistry of hepatomas. V. Studies on amino acid incorporation in liver tumors of different growth rates. Cancer Res 23: 1003-1007, 1963.
16. Sauer LA, Stayman JW and Dauchy PT: Amino acid, glucose and lactic acid utilization in vivo by rat tumors. Cancer Res 42: 4090-4092, 1982.
17. Tisdale MJ: Methionine metabolism in Walker carcinosarcoma in vitro. Br J Cancer 16: 407-414, 1980.
18. Brennan MF: Total parenteral nutrition in the cancer patient. N Engl J Med 305: 375-382, 1981.
19. Nishihira T, Takagi T and Mori S: Leucine and manifestation of antitumor activity by valine-depleted amino acid imbalance. Nutrition 9: 146-152, 1993.
20. Kovacevic Z and Morris HP: The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res 32: 326-333, 1972.
21. Quesada AR, Sánchez-Jiménez F, Pérez-Rodríguez J, Márquez J, Medina MA and Nuñez de Castro I: Purification of phosphate-dependent glutaminase from isolated mitochondria of Ehrlich ascites-tumour cells. Biochem J 255: 1031-1036, 1988.
22. Rivera S, López-Soriano FJ, Azcón-Bieto J and Argilés JM: Blood amino acid compartmentation in mice bearing Lewis lung carcinoma. Cancer Res 47: 5644-5646, 1987.
23. Zielke HR, Zielke CL and Ozand PT: Glutamine: a major energy source for cultured mammalian cells. Cancer Res 43: 121-125, 1984.
24. Lazo PA: Tumour-host metabolic interaction and cachexia. FEBS Lett 187: 189-192, 1985.
25. Argilés JM and López-Soriano FJ: Why do cancer cells have a high glycolytic rate? Med Hypotheses 32: 151-155, 1990.
26. Kern KA and Norton JA: Cancer cachexia. J Parenter Enteral Nutr 12: 286-298, 1988.
27. Harvey KB, Bothe A and Blackburn GL: Nutritional assessment and patient outcome during oncological therapy. Cancer 43: 2065-2069, 1979.
28. Nixon DW, Heymsfield SB, Kutner MM, Ansley J and Lawson DH: Protein-caloric under nutrition in hospitalized cancer patients. Am J Med 68: 491-497, 1980.
29. De Wys WD: Management of cancer cachexia. Semin Oncol 12: 452-460, 1985.
30. Argilés JM, García-Martínez C, Llovera M and López-Soriano FJ: The role of cytokines in muscle wasting: its relation with cancer cachexia. Med Res Rev 12: 637-652, 1992.
31. Adams R and Victor M (eds): Asthenia. In: Principles of Neurology. McGraw Hill, New York, pp341-345, 1981.
32. Lowry SF: Cancer cachexia revisited: old problems and new perspectives. Eur J Cancer 27: 1-3, 1991.
33. Lawson DH, Richmond A, Nixon DW and Rudman D: Metabolic approaches to cancer cachexia. Annu Rev Nutr 2: 277-301, 1982.
34. Morrison SD: Cancer cachexia. In: Influence of Tumor Development on the Host. Liotta AL (ed.) Kluwer Acad. Publ., Amsterdam, pp176-213, 1989.
35. Tisdale MJ: Cancer cachexia. Br J Cancer 63: 337-342, 1992.
36. Kien CL and Camilla BM: Increased whole-body protein turn-over in children with newly diagnosed leukemia or lymphoma. Cancer Res 43: 5592-5596, 1983.
37. Kien CL and Camitta BM: Close association of accelerated rates of whole body protein turnover (synthesis and breakdown) and energy expenditure in children with newly diagnosed acute lymphocytic leukaemia. J Parenter Enteral Nutr 11: 129-134, 1987.
38. Beck SA and Tisdale MJ: Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Res 49: 3800-3804, 1989.
39. Tessitore L, Bonelli G and Baccino FM: Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. Biochem J 241: 153-159, 1987.
40. Melville S, McNurlan MA, Graham Calder A and Garlick PJ: Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. Cancer Res 50: 1125-1131, 1990.
41. Beck SA, Smith KL and Tisdale MJ: Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51: 6089-6093, 1991.
42. Lundholm K, Ekman D, Edstrom S, Karlberg I, Jagenberg R and Scherstén T: Protein synthesis in liver tissue under the influence of a methyl-cholanthrene-induced sarcoma in mice. Cancer Res 39: 4657-4661, 1979.
43. Emery PW, Neville AM, Edwards RHT and Rennie MJ: Increased myofibrillar degradation and decreased protein synthesis in tumor-bearing mice. Eur J Clin Invest 12: 1052, 1982.
44. Pain VM, Randall DP and Garlick PJ: Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. Cancer Res 44: 1054-1057, 1984.
45. Rennie MJ, Edwards RHT, Emery PW, Halliday D, Lundholm K and Millward DJ: Depressed protein synthesis is the dominant characteristic of wasting and cachexia. Clin Physiol 3: 387-398, 1983.
46. Lundholm K, Bennegard K, Eden E, Svaninger G, Emery PW and Rennie MJ: Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. Cancer Res 42: 4807-4811, 1982.
47. Costelli P, Carbó N, Tessitore L, Bagby GJ, López-Soriano FJ, Argilés JM and Baccino FM: Tumour necrosis factor-α mediates changes in muscle protein turnover in a cachectic rat tumour model. J Clin Invest 92: 2783-2789, 1993.
48. Carbó N, Costelli P, Tessitore L, Bagby GJ, López-Soriano FJ, Baccino FM and Argilés JM: Anti-tumour necrosis factor-α treatment interferes with changes in lipid metabolism in a cachectic tumour model. Clin Sci 87: 349-355, 1994.
49. García-Martínez C, López-Soriano FJ and Argiles JM: Amino acid uptake in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma. Mol Cell Biochem 148: 17-23, 1995.
50. Llovera M, García-Martínez C, Agell N, Marzábal M, López-Soriano FJ and Argilés JM: Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 338: 311-318, 1994.
51. Llovera M, García-Martínez C, Agell N, López-Soriano FJ and Argilés JM: Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 61: 138-141, 1995.
52. Argilés JM and López-Soriano FJ: The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci 17: 223-226, 1996.
53. Adibi SA: Metabolism of branched-chain amino acids in altered nutrition. Metabolism 25: 1287-1302, 1976.
54. Block RJ: Amino Acid Handbook. Springfield, Illinois, pp344, 1956.
55. Nair KS, Schwartz RG and Welle S: Leucine as a regulator of whole body and skeletal muscle protein metabolism in humans. Am J Physiol 263: E928-E934, 1992.
56. Argilés JM and López-Soriano FJ: The oxidation of leucine in tumour-bearing rats. Biochem J 268: 241-244, 1990.
57. García-Martínez C, Llovera M, López-Soriano FJ, Del Santo B and Argilés JM: Lipopolysaccharide (LPS) increases the in vivo oxidation of branched-chain amino acids in the rat: a cytokine-mediated effect. Mol Cell Biochem 148: 9-15, 1995.
58. Goodlad GAJ, Tee MK and Clark CM: Leucine oxidation and protein degradation in the extensor digitorum longus and soleus of the tumor-bearing host. Biochem Med 26: 143-147, 1981.
59. Costelli P, Llovera M, Garcia-Martinez C, Carbó N, López-Soriano FJ and Argilés JM: Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Lett 91: 73-78, 1995.
60. Williams JF and Matthaei KI: Cancer induced body wasting. A review of cancer cachexia and a hypothesis concerning the molecular basis of the condition. Asean J Clin Sci 2: 158-173, 1981.
61. Rofe AM, Bais R and Conyers RAJ: Ketone body metabolism in tumor-bearing rats. Biochem J 233: 485-491, 1986.
62. Buse MG, Herlong HF and Weigand DA: The effects of diabetes, insulin and redox potential on leucine metabolism by isolated rat diaphragm. Endocrinology 98: 1166-1175, 1976.
63. Tessitore L, Costelli P and Baccino FM: Humoral mediation for cachexia in tumor-bearing rats. Br J Cancer 67: 15-23, 1993.
64. Lundholm KG: Energy and substrate metabolism in the cancer-bearing host. In: Nutrition in Cancer and Trauma Sepsis. Bozzetti F and Dionigi R (eds.) Karger, Basel, pp78-95, 1985.
65. Argilés JM and López-Soriano FJ: The enzymatic activities of branched-chain amino acid catabolism in tumour-bearing rats. Cancer Lett 61: 239-242, 1991.
66. Buse MG and Reid SS: Leucine, a possible regulator of protein turnover in muscle. J Clin Invest 56: 1250-1261, 1975.
67. Fulks RM, Li JB and Goldberg AL: Effects of insulin, glucose and amino acids on protein turnover in rat diaphragm. J Biol Chem 250: 290-298, 1975.
68. Tischler ME, Desautels M and Goldberg AL: Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle? J Biol Chem 257: 1613-1621, 1982.
69. Mitch WE and Clark AS: Specificity of the effects of leucine and its metabolites on protein degradation in skeletal muscle. Biochem J 222: 579-586, 1984.
70. Blomstrand E, Hassmén P, Ekblom B and Newsholme EA: Administration of branched-chain amino acids during sustained exercise: effects on performance and on plasma concentration of some amino acids. Eur J Appl Physiol 63: 83-88, 1991.
71. 13C]valine. Am J Physiol 262: E372-E376, 1992.
72. 2-adrenergic agonist (clenbuterol). J Clin Invest 95: 2367-2372, 1995.
73. Pisters PWT, Cersosimo E, Rogatko A and Brennan MF: Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery 3: 301-310, 1992.
74. Heslin MJ, Newman E, Wolf RF, Pisters PW and Brennan MF: Effect of systemic hyperinsulinemia in cancer patients. Cancer Res 52: 3845-3850, 1992.
75. Hartl WH, Miyoshi H, Jahoor F, Klein S, Elahi D and Wolfe RR: Bradykinin attenuates glucagon-induced leucine oxidation in humans. Am J Physiol 259: E239-E245, 1990.
76. Beaufrere B, Horber FF, Schwenk F, Marsh HM, Matthews D, Gerich GE and Haymond MW: Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Physiol 257: E712-E721, 1989.
77. Liu CC, Teh JY, Ou BR and Forsberg NE: Actions of a beta-adrenergic agonist on muscle protein metabolism in intact, adrenalectomized, and dexamethasone-supplemented adrenalectomized rats. J Nutr Biochem 5: 43-49, 1994.
78. Argilés JM and López-Soriano FJ: The effects of tumour necrosis factor-α (cachectin) and tumour growth on hepatic amino acid utilization in the rat. Biochem J 266: 123-126, 1990.
79. García-Martínez C, López-Soriano FJ and Argilés JM: Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Lett 87: 123-130, 1994.
80. Meguid MM, Muscaritoli M, Beverly JL, Yang ZJ, Cangiano C and Rossi-Fanelli F: The early anorexia paradigm: changes in plasma free tryptofan and feeding indexes. J Parenter Enteral Nutr 16: 56S-59S, 1992.
81. Fanelli FR, Cangiano C, Muscaritoli M, Conversano L, Torelli GF and Cascino A: Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition 11: 595-600, 1995.
82. Coley WB: The treatment of malignant tumours by repeated inoculations of erysipelas; with a report of ten original cases. Am J Med Sci 105: 487-511, 1983.
83. Old LJ: Tumor necrosis factor (TNF). Science 230: 630-632, 1985.
84. Kawakami M and Cerami A: Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 154: 631-637, 1981.
85. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R and Cerami A: Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316: 552-554, 1985.
86. Jue DM, Sherry B, Luedke C, Manogue KR and Cerami A: Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 29: 8371-8377, 1990.
87. Aggarwal BB and Natarajan K: Tumor necrosis factors: developments during last decade. Eur Cytokine Netw 7: 93-124, 1996.
88. Mahony SM and Tisdale MJ: Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. Br J Cancer 58: 345-349, 1988.
89. Socher SH, Friedman A and Martinez D: Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice. J Exp Med 167: 1211-1227, 1988.
90. Stovroff MC, Fraker DL, Swedenborg JA and Norton JA: Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. Cancer Res 48: 4567-4572, 1988.
91. Mullen BJ, Harris RBS, Patton JS and Martin RJ: Recombinant tumor necrosis factor-α chronically administered in rats: lack of cachectic effect. Proc Soc Exp Biol Med 193: 318-325, 1990.
92. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF and Cerami A: Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664, 1987.
93. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A and Socher SH: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50: 555-564, 1987.
94. Scuderi P, Lam KS, Ryan KJ, Petersen E, Sterling KE, Finley PR, Ray CG, Slymen DJ and Salmon SE: Raised serum levels of tumour necrosis factor in parasitic infections. Lancet ii: 1364-1365, 1986.
95. Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH and Vassalli P: Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237: 1210-1212, 1987.
96. Waage A, Espevik T and Lamvik J: Detection of tumor necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 24: 739-743, 1986.
97. Beutler B, Milsark IV and Cerami A: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871, 1985.
98. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM and Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318: 1481-1486, 1988.
99. Balkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H and Fiers W: Evidence for tumour necrosis factor/ cachectin production in cancer. Lancet ii: 1229-1232, 1987.
100. Saarinen UM, Kosfelo EK, Teppo AM and Simes MA: Tumor necrosis factor in children with malignancies. Cancer Res 50: 592-595, 1990.
101. Moldawer LL, Drott C and Lundholm K: Monocytic production and plasma bioactivities of interleukin-1 and tumour necrosis factor in human cancer. Eur J Clin Invest 18: 486-492, 1988.
102. Socher SH, Martinez D, Craig JB, Kuhn JG and Oliff A: Tumour necrosis factor nondetectable in patients with cancer cachexia. J Natl Cancer Inst 80: 595-598, 1988.
103. Selby PJ, Hobbs S, Niner C, Jackson E, Smith IE and McElwain TJ: Endogenous tumour necrosis factor in cancer patients. Lancet i: 483, 1988.
104. Stovroff MC, Fraker DL and Norton JA: Cachectin activity in the serum of cachectic, tumor-bearing rats. Arch Surg 124: 94-99, 1988.
105. Aderka D, Fischer D, Levo Y, Holtmann H, Hahn T and Wallach D: Cachectin/tumour necrosis factor production by cancer patients. Lancet ii: 1190, 1985.
106. Fong Y, Moldawer LL, Morano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fischman DA, Cerami A and Lowry SF: Cachectin/TNF or IL-1α induces cachexia with redistribution of body proteins. Am J Physiol 256: R659-R665, 1989.
107. Warren RS, Starnes HF Jr, Gabrilove JL, Oettgen HF and Brennan MF: The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 122: 1396-1400, 1987.
108. Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL and Istfan NW: Infusion of tumor necrosis factor/ cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin1. J Clin Invest 83: 1614-1622, 1989.
109. Goodman MN: Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 260: E727-E730, 1991.
110. Llovera M, López-Soriano FJ and Argilés JM: Effects of tumour necrosis factor-α on muscle protein turnover in vivo in female rats. J Natl Cancer Inst 85: 1334-1339, 1993.
111. Llovera M, López-Soriano FJ and Argilés JM: Chronic tumour necrosis factor-α treatment modifies protein turnover in rat tissues. Biochem Mol Biol Int 30: 29-36, 1993.
112. García-Martínez C, López-Soriano FJ and Argiles JM: Acute treatment with tumour necrosis factor-α induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem 125: 11-18, 1993.
113. García-Martínez C, Agell N, Llovera M, López-Soriano FJ and Argilés JM: Tumour necrosis factor-α increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett 323: 211-214, 1993.
114. García-Martínez C, Llovera M, Agell N, López-Soriano FJ and Argilés JM: Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-α. Biochem Biophys Res Commun 201: 682-686, 1994.
115. Hershko A, Ciechanover A, Heller H, Haas AL and Rose IA: Proposed role of ATP in protein breakdown: conjugation of proteins with multiple chains of polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA 77: 1783-1786, 1980.
116. Ciechanover A, Finley D and Varshavsky A: The ubiquitin-dependent pathway and mechanisms of energy-dependent intracellular protein degradation. J Cell Biochem 24: 27-53, 1984.
117. Finley D and Varshavsky A: The ubiquitin system: functions and mechanisms. Trends Biochem Sci 10: 343-347, 1985.
118. Finley D and Chan V: Ubiquitination. Annu Rev Cell Biol 7: 25-69, 1991.
119. Rechsteiner JM: Natural substrates of the ubiquitin proteolytic pathway. Cell 66: 615-618, 1991.
120. Peters JM: Proteasomes: protein degradation machines of the cell. Trends Biochem Sci 19: 377-382, 1994.
121. Hilenski LL, Terracio L, Haas AL and Borg TK: Immunolocalization of ubiquitin conjugates at Z-bands and intercalates discs of rat cardiomyocytes in vitro and in vivo. J Histochem Cytochem 40: 1037-1042, 1992.
122. Costelli P, Llovera M, Carbó N, García-Martínez C, López-Soriano FJ and Argilés JM: Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett 95: 33-38, 1995.
123. Llovera M, García-Martínez C, Costelli P, Agell N, Carbó N, López-Soriano FJ and Argilés JM: Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Lett 99: 7-14, 1996.
124. Tartaglia LA and Goeddel DV: Two TNF receptors. Immunol Today 13: 151-153, 1992.
125. Llovera M, García-Martínez C, Agell N, López-Soriano FJ and Argilés JM: TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 230: 238-241, 1997.
126. Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F and Nordan RP: Suramin interfers with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 92: 2152-2159, 1993.
127. Soda K, Kawakami M, Kashii A and Miyata M: Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia. Jpn J Cancer Res 85: 1124-1130, 1994.
128. Soda K, Kawakami M, Kashii A and Miyata M: Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 62: 332-336, 1995.
129. García-Martínez C, López-Soriano FJ and Argiles JM: lnterleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Lett 76: 1-4, 1994.
130. Matthys P, Heremans H, Opdenakker G and Billiau A: Antiinterferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 27: 182-187, 1991.
131. Matthys P, Dukmans R, Proost P, van Damme J, Heremans H, Sobis H and Billiau A: Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer 49: 77-82, 1991.
132. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O and Abe K: Cancer cahexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitor factor. Cancer Res 51: 6656-6659, 1991.
133. Zugmaier G, Paik S, Wilding G, Knabbe K, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB and Lippman M: Transforming growth factor B1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res 51: 3590-3594, 1991.
134. Moldawer LL, Georgieff M and Lundholm K: Interleukin-1, tumor necrosis factor-α/cachectin and the pathogenesis of cancer cachexia. Clin Physiol 7: 263-274, 1987.
135. Mrosovsky N, Molony LA, Conn CA and Kluger MJ: Anorexic effects of interleukin 1 in the rat. Am J Physiol 257: R1315-R1321, 1989.
136. Hashimoto M: Characterization and mechanism of fever induction by interleukin-1-beta. Pflugers Arch 419: 616-621, 1991.
137. Costa G and Holland JF: Effects of Krebs-2 carcinoma on the lipid metabolism of male Swiss mice. Cancer Res 22: 1081-1083, 1966.
138. Masuno H, Yamaskai N and Okuda H: Purification and characterization of a lipolytic factor (Toxohormone L) from cell free fluid of ascites sarcoma 180. Cancer Res 41: 284-288, 1981.
139. Kitada S, Hays EF and Mead JF: A lipid mobilizing factor in serum of tumor-bearing mice. Lipids 15: 168-174, 1980.
140. Kitada S, Hays EF and Mead JF: Characterization of a lipid mobilizing factor from tumors. Prog Lipid Res 20: 823-826, 1981.
141. Kitada S, Hays EF and Mead JF: Lipolysis induction in adipocytes by a protein from tumour cells. J Cell Biochem 20: 409-416, 1982.
142. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K and Tisdale M: Characterization of a cancer cachectic factor. Nature 22: 739-742, 1996.